MedTrace Logo

A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients

NCT03239691 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-08-31

No results posted yet for this study

Summary

The main study objective is to assess the effect of ACT-709478 in male and female subjects with photosensitive epilepsy following single dose administration

Conditions

  • Photosensitive Epilepsy

Interventions

DRUG

ACT-709478 for oral use

Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg

DRUG

Placebo

Matching placebo available as matching capsules for oral administration

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-06
Primary Completion
2018-04-25
Completion
2018-04-25

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03239691 on ClinicalTrials.gov